Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

• DOI: 10.1136/jitc-2021-002435
• Publication Date: 2021-06-25T16:30:54Z
• Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Asc...; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
• Keywords: Guideline; Clinical Practice; Cancer Immunotherapy

Immune checkpoint inhibitors (ICIs) are the standard of care for treatment several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks toxicity, specifically immune-related adverse events (irAEs). There is a need clear, effective guidelines management irAEs during ICI treatment, motivating Society Immunotherapy Cancer (SITC) to convene an expert panel develop practice guideline. The discussed recognition and single combination ultimately developed evidence- consensus-based recommendations assist medical professionals decision-making improve patients.